Case-Based Review of Breast Imaging Changes Associated With GLP-1 Agonists

Abstract Purpose of Review This article will review several cases demonstrating breast imaging findings following the use of glucagon-like peptide-1 (GLP-1) agonists, including the relevant implications in changing breast density and supplemental screening. Recent Findings GLP-1 agonists may be associated with breast changes and symptoms that warrant further breast imaging, including supplemental screening and/or for problem solving in the appropriate clinical scenario. Summary Breast imaging findings following the use of GLP-1 agonists may vary, including both significant and insignificant increases in breast density. Patients with increased breast density may warrant further evaluation with supplemental screening. Following the use of GLP-1 agonists, patients may also present with symptoms warranting further targeted imaging evaluation. Knowledge of the spectrum of breast changes associated with GLP-1 agonists is necessary to adequately assess the need for supplemental screening and/or additional targeted breast imaging.